Amplification and overexpression of the MDM4 (MDMX) gene from 1q32 in a subset of malignant gliomas without TP53 mutation or MDM2 amplification

被引:0
|
作者
Riemenschneider, MJ
Büschges, R
Wolter, M
Reifenberger, J
Boström, J
Kraus, JA
Schlegel, U
Reifenberger, G
机构
[1] Univ Bonn, Med Ctr, Dept Neuropathol, D-53105 Bonn, Germany
[2] Univ Bonn, Med Ctr, Dept Neurosurg, D-53105 Bonn, Germany
[3] Univ Bonn, Med Ctr, Dept Neurol, D-53105 Bonn, Germany
[4] Univ Dusseldorf, Dept Dermatol, D-40225 Dusseldorf, Germany
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We have previously reported on the amplification and overexpression of the MDM2 proto-oncogene in a subset of malignant gliomas without TP53 mutation (G. Reifenberger et al., Cancer Res., 53: 2736-2739, 1993). Here, we show that the MDM4 (MDMX) gene located on 1q32 is a further target for amplification in malignant gliomas. MDM4 codes for a Mdm2-related protein that can bind to p53 and inhibits p53-mediated transcriptional transactivation. We investigated a series of 208 gliomas (106 glioblastomas, 46 anaplastic gliomas, and 56 low-grade gliomas) and identified 5 tumors (4 glioblastomas and 1 anaplastic oligodendroglioma) with MDM4 amplification and overexpression. Several other genes from 1q32 were found to be coamplified with MDM4, such as GAC1 in five tumors, REN in four tumors, and RBBP5 in three tumors. Additional analyses revealed that the malignant gliomas with MDM4 amplification and overexpression carried neither mutations in conserved regions of the TP53 gene nor amplification of the MDM2 gene. Taken together, our data indicate that amplification and overexpression of MDM4 is a novel molecular mechanism by which a small fraction of human malignant gliomas escapes p53-dependent growth control.
引用
收藏
页码:6091 / 6096
页数:6
相关论文
共 50 条
  • [1] Refined mapping of 1q32 amplicons in malignant gliomas confirms MDM4 as the main amplification target
    Riemenschneider, MJ
    Knobbe, CB
    Reifenberger, G
    INTERNATIONAL JOURNAL OF CANCER, 2003, 104 (06) : 752 - 757
  • [2] AMPLIFICATION AND OVEREXPRESSION OF THE MDM2 GENE IN A SUBSET OF HUMAN-MALIGNANT GLIOMAS WITHOUT P53 MUTATIONS
    REIFENBERGER, G
    LIU, L
    ICHIMURA, K
    SCHMIDT, EE
    COLLINS, VP
    CANCER RESEARCH, 1993, 53 (12) : 2736 - 2739
  • [3] Refined mapping of 1q32 amplicons in human malignant gliomas confirms MDM4 as the main amplification target
    Riemenschneider, MJ
    Reifenberger, G
    ACTA NEUROPATHOLOGICA, 2002, 104 (05) : 566 - 566
  • [4] Infrequent mutations of the TP53 gene and no amplification of the MDM2 gene in hepatoblastomas
    Ohnishi, H
    Kawamura, M
    Hanada, R
    Kaneko, Y
    Tsunoda, Y
    Hongo, T
    Bessho, F
    Yokomori, K
    Hayashi, Y
    GENES CHROMOSOMES & CANCER, 1996, 15 (03): : 187 - 190
  • [5] MDM2 GENE AMPLIFICATION AND TRANSCRIPT LEVELS IN HUMAN SARCOMAS - RELATIONSHIP TO TP53 GENE STATUS
    FLORENES, VA
    MAELANDSMO, GM
    FORUS, A
    ANDREASSEN, A
    MYKLEBOST, O
    FODSTAD, O
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1994, 86 (17) : 1297 - 1302
  • [6] Rare MDM4 gene amplification in colorectal cancer: The principle of a mutually exclusive relationship between MDM alteration and TP53 inactivation is not applicable
    Suda, Tetsuji
    Yoshihara, Mitsuyo
    Nakamura, Yoshiyasu
    Sekiguchi, Hironobu
    Godai, Ten-I
    Sugano, Nobuhiro
    Tsuchida, Kazuhito
    Shiozawa, Manabu
    Sakuma, Yuji
    Tsuchiya, Eiju
    Kameda, Yoichi
    Akaike, Makoto
    Matsukuma, Shoichi
    Miyagi, Yohei
    ONCOLOGY REPORTS, 2011, 26 (01) : 49 - 54
  • [7] MDM2 AMPLIFICATION AND P53 MUTATION IN MALIGNANT FIBROUS HISTIOCYTOMA
    REID, AH
    TSAI, MM
    WRIGHT, CF
    VENZON, DJ
    OLEARY, TJ
    JOURNAL OF CELLULAR BIOCHEMISTRY, 1994, : 202 - 202
  • [8] Chronic lymphocytic leukemia with MDM2 amplification as an alternative pathway to TP53 dysfunction
    Hunter, Sally
    Ryland, Georgina
    Pang, Jia-Min
    Ninkovic, Slavisa
    Dun, Karen
    Seymour, John F.
    Blombery, Piers
    LEUKEMIA & LYMPHOMA, 2024, 65 (14) : 2215 - 2218
  • [9] Prognostic value of MGMT promoter hypermethylation, TP53 mutation, MDM2, EGFR and CDK4 amplification in malignant glioma patients
    Loeser, S
    Luyken, C
    Blaschke, B
    Köhler, S
    Kreuzmann, A
    Seghrouchni, S
    Reifenberger, G
    Sabel, M
    ACTA NEUROPATHOLOGICA, 2005, 110 (03) : 332 - 332
  • [10] Effects of MDM2, MDM4 and TP53 Codon 72 Polymorphisms on Cancer Risk in a Cohort Study of Carriers of TP53 Germline Mutations
    Fang, Shenying
    Krahe, Ralf
    Lozano, Guillermina
    Han, Younghun
    Chen, Wei
    Post, Sean M.
    Zhang, Baili
    Wilson, Charmaine D.
    Bachinski, Linda L.
    Strong, Louise C.
    Amos, Christopher I.
    PLOS ONE, 2010, 5 (05):